聚乳酸膜改善中厚皮片供区结局:一项前瞻性、比较性、随机研究
该随机临床试验将需行中厚皮片移植的患者分配至供区使用聚乳酸膜或聚氨酯膜,每组30例。术后3个月温哥华瘢痕量表评分聚乳酸膜组中位数2分低于聚氨酯膜组3分(p=0.049),换药疼痛和活动时疼痛更轻,每日换药次数更少、每次换药时间更短,但聚乳酸膜组费用更高。
要点
- 聚乳酸膜组供区瘢痕温哥华瘢痕量表评分中位数2分,低于聚氨酯膜组的3分(p=0.049)。
- 聚乳酸膜组换药疼痛(0.5±0.2 vs 2.0±0.2)和活动疼痛(0.3±0.1 vs 0.8±0.2)均低于聚氨酯膜组。
- 聚乳酸膜组每住院日换药次数更少、每次换药时间更短,但费用高于聚氨酯膜组。
核心结论
- 聚乳酸膜改善中厚皮片移植供区结局,但必须考虑更高的治疗费用。
研究设计与样本
- 随机临床试验,将需行中厚皮片移植的患者分配至供区使用聚乳酸膜或聚氨酯膜,每组30例。
- 主要终点为术后3个月采用温哥华瘢痕量表评估的供区瘢痕外观差异。
- 次要终点包括疼痛、换药次数和换药所需时间以及与伤口敷料相关的费用。
- 证据等级:治疗性,II级。
主要发现
- 温哥华瘢痕量表评分中位数聚乳酸膜组为2分(四分位距1至3),聚氨酯膜组为3分(四分位距2至4),p=0.049。
- 换药时疼痛聚氨酯膜组2.0±0.2 vs 聚乳酸膜组0.5±0.2,p<0.001;活动时疼痛聚氨酯膜组0.8±0.2 vs 聚乳酸膜组0.3±0.1,p=0.032。
- 每住院日换药次数聚氨酯膜组0.44±0.06 vs 聚乳酸膜组0.28±0.02,p=0.015。
- 每例患者平均换药时间聚氨酯膜组74.50±5.72分钟 vs 聚乳酸膜组21.43±2.61分钟,p<0.001。
- 费用聚乳酸膜组€162.79±€21.76 vs 聚氨酯膜组€67.83±€5.56,p<0.001,聚乳酸膜组更高。
临床怎么用
- 作者认为聚乳酸膜改善中厚皮片移植供区结局,但必须考虑更高的治疗费用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polyurethane film dressings are commonly applied for coverage of split-thickness skin graft donor sites, although previous studies have suggested reduced morbidity using a polylactic acid membrane. To further investigate the optimal treatment approach, the authors compared outcomes of donor sites in patients receiving either polylactic acid membrane or polyurethane film. METHODS: This randomized clinical trial allocated patients requiring split-thickness skin grafting to receive either polylactic acid membrane or polyurethane film at the donor site. The primary endpoint was difference in donor-site scar appearance between groups 3 months postoperatively, using the Vancouver Scar Scale. Secondary endpoints included pain, number of and time required for wound dressing changes, and costs related to the wound dressing. RESULTS: Thirty patients were allocated to each group. The median Vancouver Scar Scale score was lower for patients receiving polylactic acid membrane [polyurethane film, 3 (interquartile range, 2 to 4); polylactic acid membrane, 2 (interquartile range, 1 to 3); p = 0.049]. Pain during change of wound dressing (polyurethane film, 2.0 ± 0.2; polylactic acid membrane, 0.5 ± 0.2; p < 0.001) and mobilization (polyurethane film, 0.8 ± 0.2; polylactic acid membrane, 0.3 ± 0.1; p = 0.032) were reduced in the polylactic acid membrane group. Patients with polylactic acid membrane required fewer dressing changes per day of hospital stay (polyurethane film, 0.44 ± 0.06; polylactic acid membrane, 0.28 ± 0.02; p = 0.015). Mean time for wound dressing changes per patient was higher in the polyurethane film group (polyurethane film, 74.50 ± 5.72 minutes; polylactic acid membrane, 21.43 ± 2.61 minutes; p < 0.001). Costs were higher in the polylactic acid membrane group (polyurethane film, €67.83 ± €5.56; polylactic acid membrane, €162.79 ± €21.76; p < 0.001). CONCLUSION: Polylactic acid membrane improves outcome of split-thickness skin grafting donor sites; however, higher treatment costs must be taken into consideration. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.
引用
- Moellhoff N, Lettner M, Frank K, et al. Polylactic Acid Membrane Improves Outcome of Split-Thickness Skin Graft Donor Sites: A Prospective, Comparative, Randomized Study. Plast Reconstr Surg. 2022. PMID: 36067484. doi:10.1097/PRS.0000000000009629
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。